To investigate the association of Alvimopan on gastrointestinal recovery and length of hospitalisation in men undergoing Retroperitoneal lymph node dissection (RPLND) for testicular cancer

Trial Profile

To investigate the association of Alvimopan on gastrointestinal recovery and length of hospitalisation in men undergoing Retroperitoneal lymph node dissection (RPLND) for testicular cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Alvimopan (Primary)
  • Indications Testicular cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top